| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| NSD1 (E2U6H) Rabbit mAb | 51076 | 20 µl | 300 kDa | Rabbit IgG |
| WHSC1 (D4Z8Q) Rabbit mAb | 65127 | 20 µl | 66, 152 kDa | Rabbit IgG |
| WHSC1L1 (D4N9N) Rabbit mAb | 92056 | 20 µl | 80-90, 180 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The NSD Family Antibody Sampler Kit provides an economical means of detecting NSD protein family members. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Storage
Background
The nuclear receptor SET domain-containing (NSD) family of histone H3 lysine 36 (H3K36) methyltransferases contains the NSD1, WHSC1/NSD2, and WHSC1L1/NSD3 proteins. More specifically, these enzymes catalyze mono- and di-methylation of H3K36, marks that are typically associated with transcriptionally active regions of the genome (1,2). NSD1 is required for proper embryonic development (3), and mutations in NSD1 are believed to be major contributing factors to the overgrowth disorder, Sotos syndrome (4-6). NSD1 is also mutated or has altered expression in several types of cancer and is thought to exert tumor suppressive or promoting functions depending on cellular context (7-11). WHSC1/NSD2 haploinsufficiency is implicated in the developmental disorder, Wolf-Hirschhorn syndrome, which is characterized by delayed growth, mental retardation, and congenital heart defects (12). In addition, WHSC1 is overexpressed and associated with poor prognosis in a large variety of human cancers, including neuroblastoma and ovarian, hepatocellular, endometrial, and colorectal carcinoma (13-17). WHSC1L1/NSD3 can function as an oncogene or a tumor suppressor protein and has been shown to regulate expression of several genes associated with cell cycle (18). Amplification and/or increased expression of WHSC1L1/NSD3 in breast, lung, and liver cancer increases growth and survival, and is associated with poor prognosis (18-21).
- Wagner, E.J. and Carpenter, P.B. (2012) Nat Rev Mol Cell Biol 13, 115-26.
- Bennett, R.L. et al. (2017) Cold Spring Harb Perspect Med 7, a026708. doi: 10.1101/cshperspect.a026708.
- Rayasam, G.V. et al. (2003) EMBO J 22, 3153-63.
- Kurotaki, N. et al. (2002) Nat Genet 30, 365-6.
- Douglas, J. et al. (2003) Am J Hum Genet 72, 132-43.
- Rio, M. et al. (2003) J Med Genet 40, 436-40.
- Bianco-Miotto, T. et al. (2010) Cancer Epidemiol Biomarkers Prev 19, 2611-22.
- Zhang, S. et al. (2019) J Exp Clin Cancer Res 38, 467.
- Cancer Genome Atlas Network collaborators (2015) Nature 517, 576-82.
- Berdasco, M. et al. (2009) Proc Natl Acad Sci USA 106, 21830-5.
- Krossa, I. et al. (2022) Cancers (Basel) 14, 4865. doi: 10.3390/cancers14194865.
- Stec, I. et al. (1998) Hum Mol Genet 7, 1071-82.
- Hudlebusch, H.R. et al. (2011) Clin Cancer Res 17, 2919-33.
- Yang, S. et al. (2013) Biomarkers 18, 257-63.
- Zhou, P. et al. (2013) Pathol Oncol Res 19, 303-9.
- Xiao, M. et al. (2013) J Surg Oncol 107, 428-32.
- Hudlebusch, H.R. et al. (2011) Cancer Res 71, 4226-35.
- Zhou, Z. et al. (2010) Biochem Biophys Res Commun 398, 565-70.
- Angrand, P.O. et al. (2001) Genomics 74, 79-88.
- Yang, Z.Q. et al. (2010) Cancer Res 70, 8487-97.
- Kang, D. et al. (2013) Genes Chromosomes Cancer 52, 126-39.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.